$CLSDQ News

New Strong Sell Stocks for January 21st

AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Tops Revenue Estimates

How Recent Moves Are Rewriting the Story for Clearside Biomedical

Clearside Biomedical Announces Multiple Presentations on Suprachoroidal Delivery to be Featured at the 25th EURETINA Congress

Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada

Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline

Shareholders in Clearside Biomedical (NASDAQ:CLSD) are in the red if they invested five years ago

Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting

Clearside Biomedical (CLSD) Upgraded to Buy: Here's What You Should Know

Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum

Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Tops Revenue Estimates

Clearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate Update

Clearside Biomedical Data Featured in Six Presentations at Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting

Clearside Biomedical to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025

Clearside Biomedical to Participate in a Fireside Chat at the Citizens Life Sciences Conference

Clearside Biomedical Inc (CLSD) Q4 2024 Earnings Call Highlights: Strategic Advances and ...

Clearside Biomedical to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

Clearside Biomedical Full Year 2024 Earnings: In Line With Expectations

Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Tops Revenue Estimates

Clearside Biomedical, Inc. (CLSD) Q4 2024 Earnings Conference Call Transcript